U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

  1. Home
  2. Drugs
  3. Drug Safety and Availability
  4. Postmarket Drug Safety Information for Patients and Providers
  5. Sleep Disorder (Sedative-Hypnotic) Drug Information
  1. Postmarket Drug Safety Information for Patients and Providers

Sleep Disorder (Sedative-Hypnotic) Drug Information

Sedative-hypnotic drug products are a class of drugs used to induce and/or maintain sleep.

FDA Drug Safety Communications:

Prescription Insomnia Drugs (UPDATED)

For prescribing information, please search the Drugs@FDA database.

  • Ambien (zolpidem)
  • Belsomra (suvorexant)
  • Butisol (butabarbital)
  • Dayvigo (lemborexant)
  • Doral (quazepam)
  • Edluar (zolpidem)
  • Estazolam
  • Flurazepam
  • Halcion (triazolam)
  • Hetlioz (tasimelteon)
  • Intermezzo (zolpidem)
  • Lunesta (eszopiclone)
  • Quviviq (daridorexant) 
  • Restoril (temazepam)
  • Rozerem (ramelteon)
  • Seconal (secobarbital)
  • Silenor (doxepin)
  • Sonata (zaleplon)
  • Zolpimist (zolpidem)

Over-the-counter (OTC) Insomnia Drugs

  • Benadryl (diphenhydramine)*
  • Unisom (doxylamine)*

*Also in many cold and headache combination products

Related Information

Back to Top